Clinical trials: Pituitary Diseases
Cushing's Disease
Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)
RATIONALE: Rosiglitazone may help pituitary tumor cells become more like normal cells, and to grow and spread more slowly. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with newly…
- Trial name
- NCT00612066
- Testing
- rosiglitazone maleate
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Pain, Postoperative, Analgesia
Analgesia Nociception Index (ANI) in Intracranial Surgical Anesthesia
In our study, 75 patients aged 18-80 years, classified as ASA I-II risk groups, who underwent intracranial surgery performed by the Department of Neurosurgery at Trakya University Faculty of Medicine Hospital, were included.
- Conditions
- Pain, Postoperative, Analgesia, Supratentorial Brain Tumor, Infratentorial Neoplasms
- Trial name
- ANI (NCT06752824)
- Testing
- ANALGESIA NOCICEPTION INDEX MONITORING
- Where
- Turkey (Türkiye)
- Volunteers
- 75 people
- Sponsor
- Trakya University
Brain Tumors
Fluorescence Guided Resection of Brain Tumors
Removing a tumor from your brain is hard to do because, very often, brain tumors do not have boundaries that are easy for your surgeon to find. In many cases, the surgeon can't tell exactly where the tumor begins or ends.
- Trial name
- FGR (NCT00870779)
- Testing
- 5-aminolevulinic acid
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- David W. Roberts
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors…
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor
- Trial name
- NCT01088763
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 12 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- National Cancer Institute (NCI)
Pituitary Adenoma
Detection of Functioning Pituitary Microadenoma: PET/MRI Versus PET/CT
This is a prospective case-control study to compare the usefulness of 18F-FDG PET/MRI with that of 18F-FDG PET/CT in detection of functioning pituitary microadenomas.A single dose of 370 Mega-Becquerel (MBq) 18F-FDG will be…
- Trial name
- NCT03404414
- Testing
- 18F-FDG
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Risperidone-induced Hyperprolactinemia
Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia
The purpose of this study is to determine whether calcium and vitamin D supplementation, over a nine-month period, optimizes bone mineralization in boys with risperidone-induced hyperprolactinemia.
- Trial name
- NCT00799383
- Testing
- Calcium and Vitamin D
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Chadi A. Calarge
Cardiovascular Diseases, Heart Diseases
Pilot Study of Using Copeptin to Predict Response to Tolvaptan
This pilot study will investigate the association between levels of the peptide copeptin and response to tolvaptan, a drug that blocks the action of the water retaining hormone vasopressin.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Heart Failure
- Trial name
- NCT01346072
- Testing
- tolvaptan
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of North Carolina, Chapel Hill
Hyponatremia, Syndrome of Inappropriate Antidiuresis
Protein Supplementation in Hyponatremia Due to the Syndrome of Inappropriate Antidiuresis
The goal of this study is to assess the impact of protein supplementation on hyponatremia caused by the syndrome of inappropriate antidiuresis during hospitalization.
- Trial name
- TREASUREx (NCT06821802)
- Testing
- Moltein PURE Protein Powder, Fluid restriction
- Where
- Switzerland
- Volunteers
- 70 people
- Sponsor
- University Hospital, Basel, Switzerland
Cushing Disease Due to Increased ACTH Secretion
Combination Osilodrostat and Cabergoline in Cushing's Disease
Cushing disease remains a challenging endocrine disorder in which persistent or recurrent hypercortisolism often requires medical therapy after surgery or when surgery is not feasible.
- Trial name
- COSCA-ECD (NCT07603466)
- Testing
- osilodrostat, osilodrostat and cabergoline
- Where
- 5 sites in Iraq
- Volunteers
- 50 people
- Sponsor
- University of Basrah
Growth Hormone Deficiency, Endocrine System Diseases
A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
A 38-week dosing trial of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus placebo-control.
- Conditions
- Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
- Trial name
- foresiGHt (NCT04615273)
- Testing
- Lonapegsomatropin, Somatropin
- Where
- 113 sites in United States, Armenia and 22 more
- Volunteers
- 264 people
- Sponsor
- Ascendis Pharma Endocrinology Division A/S
Inappropriate ADH Syndrome
Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study
Empagliflozin (Jardiance)® is a sodium glucose co-transporter 2 (SGLT2)-Inhibitor, which is a new treatment option developed for patients with diabetes mellitus type 2.
- Trial name
- DIVE (NCT02729766)
- Testing
- Induced hypotonic hyponatremia - SIAD model, Empagliflozin 25mg Tbl
- Where
- Switzerland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Endocrine System Diseases, Thyroid Diseases
Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors
The aim of this study is to assess the impact of endocrine changes and their correction on survival and organ function in heart and lung transplant recipients.
- Conditions
- Endocrine System Diseases, Thyroid Diseases, Cortisol Deficiency, Diabetes Insipidus
- Trial name
- NCT04351945
- Testing
- Blood test
- Where
- Hungary
- Volunteers
- 100 people
- Sponsor
- Semmelweis University Heart and Vascular Center
Growth Hormone Deficiency
Reference Values for Body Composition Parameters and IGF-I in the Adult NordiNet® International Outcome Study
The treatment of Growth Hormone deficiency (GHD) patients with GH, often induce fluid retention; this effect is dose dependent and temporary. The symptoms are swelling of soft tissue and joint stiffness.
- Trial name
- NCT01120977
- Where
- Denmark
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Cushing's Disease
Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease
Background: Cushing s disease is caused by excess ACTH hormone release by a benign tumor of the pituitary gland. It can lead to decreased quality of life and early death.
- Trial name
- NCT04339751
- Testing
- Vorinostat
- Where
- United States
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Shock, Septic
Multimodal Vasopressor Strategy in Septic Shock
The goal of this prospective randomized controlled trial is to compare the effects of classic stepwise vs. early balanced multimodal vasopressor strategies in septic shock.
- Trial name
- NCT06155812
- Testing
- Simultaneous administration of vasopressors, Successive administration of vasopressors
- Where
- 2 sites in Croatia, Slovenia
- Volunteers
- 79 people
- Sponsor
- University Medical Centre Maribor
Pituitary Adenoma 1, Acth-Secreting
Pituitary Adenoma and Serum Lipid
Pituitary adenomas are usually benign monoclonal neoplasms caused by a mixture of pituicyte alterations together with a changed endocrine and paracrine regulatory milieu.
- Trial name
- NCT04021212
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Shandong Provincial Hospital
Cushings Disease, Cushing Disease
Safety and Efficacy of LCI699 in Cushing's Disease Patients
This exploratory study is a proof of concept study to determine whether LCI699 can safely reduce the level of urinary free cortisol in patients with Cushing's disease.
- Trial name
- NCT01331239
- Testing
- LCI699
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma, Glial Tumor
Evaluation of the CONVIVO System
The primary objective of this study is to evaluate the diagnostic performance of the CONVIVO confocal endomicroscope in discriminating between normal and abnormal tissue in vivo during brain tumor surgery.
- Conditions
- Glioblastoma, Glial Tumor, Brain Metastases, Meningioma
- Trial name
- NCT05139277
- Testing
- CONVIVO system, Conventional histologic evaluation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Acromegaly
Validation Study of the SAGIT® Instrument in Acromegaly
Patients will be treated in accordance with the standard medical practice of the hospital where they have been recruited during their participation in this study. No additional assessments or tests will be required.
- Trial name
- SAGIT (NCT02539927)
- Where
- 33 sites in United States, Belgium and 8 more
- Volunteers
- 227 people
- Sponsor
- Ipsen
Hypopituitarism, Pituitary Tumors
Effect of 5 Years of GH Replacement on Atherosclerosis
Adult patients with hypopituitarism under adequate conventional hormone replacement therapy have reduced life expectancy due to excess vascular events (1-4).
- Conditions
- Hypopituitarism, Pituitary Tumors, Growth Hormone Deficiency
- Trial name
- 5yrGH (NCT00462475)
- Testing
- Recombinant Growth Hormone, Genotropin (Pfizer)
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Federico II University